× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach


darunavir/cobicistat plus chloroquine

adjuvant therapies

anticoagulant 2

anticoagulant, curative dose 3

anticoagulant, prophylactic dose 4

anticoagulation, intermediate prophylactic dose 1

Bivalirudin

heparin at therapeutic dose 3

sulodexide

colchicine 5

face mask

febuxostat

hydrogen-oxygen nebulizer

hyperbaric oxygen

nintedanib

pulmonary rehabilitation

thalidomide

vitamin C 4

anti-inflammatoty and immuno-therapy

acalabrutinib 2

anti-inflammatory therapies 1

IFX-1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs 5

Celecoxib 1

Ibuprofen 1

Indomethacin 1

sodium aescinate

Apilimod

corticosteroids 7

ciclesonide

dexamethasone 3

Hydrocortisone 4

inhaled corticosteroids 1

low-dose corticosteroids

methylprednisolone 5

imatinib

Immunostimulants drugs

anti-PD-1 antibody

CD24Fc

convalescent plasma treatment 21

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

interferon 1

IFN beta-1a 3

high-dose IFN beta-1a 1

IFN beta-1b 2

IFN gamma 1

inhaled interferon

recombinant super-compound interferon rSIFN-co 1

SNG001 inhaled interferon beta 1

interferon / TFF2 1

peginterferon 2

Interleukin-2

neutralizing antibody

AZD7442

bamlanivimab monotherapy 2

bamlanivimab plus etesevimab 3

BRII-196 and BRII-198 (Brii Biosciences)

casirivimab and imdevimab (REGN-COV2) 1

regdanvimab (CT-P59 Celltrion) 1

VIR-7831 / GSK4182136 2

rhG-CSF

Vitamin D 7

Immunosuppressants drugs

anakinra 3

anti-interleukin-6

clazakizumab

sarilumab 4

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab 24

baricitinib

baricitinib plus remdesivir 1

eculizumab

jakotinib

lenzilumab 1

ruxolitinib 2

tacrolimus

tetrandrine

leflunomide 1

pirfenidone

Polyinosinic-Polycytidylic Acid

sargramostim

thymosin

antiandrogenic

5-alpha-reductase inhibitors

antiviral and associated therapy

ASC09/ritonavir

azithromycin 9

azvudine 1

baloxavir marboxil 1

carrimycin

chloroquine and derivatives

chloroquine 5

hydroxychloroquine 42

danoprevir / ritonavir

darunavir cobicistat 1

doxycycline 2

favipiravir 15

fluvoxamine 1

hydroxychloroquine plus macrolides 8

ivermectin 27

leronlimab

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 6

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b 1

meplazumab

nitazoxanide

oseltamivir 2

oseltamivir plus chloroquin

remdesivir 5

Renin-angiotensin-system-acting agents 7

angiotensin converting enzyme inhibitors (ACEIs)

angiotensin receptor blockers (ARBs) 2

angiotensin-(1-7)

discontinuation of ACEI/ARB 2

RAS blocker withdrawal

rhACE2

ritonavir

sofosbuvir and daclatasvir 3

sofosbuvir and ledipasvir 1

tranexamic acid

triazavirin

umifenovir (arbidol) 5

clarithromycine

control

prone positioning

honey

miscellaneous

acetylcysteine

alpha lipoic acid 1

aviptadil

bevacizumab

bismuth

BLD-2660 (calpain inhibitor)

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

dipyridamol

DPP-4 inhibitor

enoxaparin

famotidine 1

kinin-kallikrein inhibitors

levamisole

metformin

natural killer (NK) cells

nicotin

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

pamrevlumab

povidone-iodine

proton pump inhibitors (PPI) 6

proxalutamide

PUL-042 inhalation solution

radiotherapy

selinexor

statins

tradipitant

tranilast

zinc 3

vaccines

BCG vaccination

DNA vaccine

bacTRL-Spike

stem cells 3

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons